SEARCH

SEARCH BY CITATION

References

  • Alcock NW, Crout DHG, Gregorio MVM, Lee E, Pike G & Samuel CJ (1989) Stereochemistry of the 4-hydroxyisoleucine from Trigonella foenum-graecum. Phytochemistry 28: 18351841.
  • Berger BJ, English S, Chan G & Knodel MH (2003) Methionine regeneration and aminotransferases in Bacillus subtilis, Bacillus cereus, and Bacillus anthracis. J Bacteriol 185: 24182431.
  • Broca C, Gross R, Petit P, Sauvaire Y, Manteghetti M, Turnier M, Masiello P, Gomis R & Ribes G (1999) 4-Hydroxyisoleucine: experimental evidence of its insulinotropic and antidiabetic properties. Am J Physiol Endocrinol Metab 277: 617623.
  • Broca C, Breil V, Cruciani-Guglielmacci C et al. (2004) Insulinotropic agent ID-1101 (4-hydroxyisoleucine) activates insulin signaling in rat. Am J Physiol Endocrinol Metab 287: 463471.
  • Fowden L, Pratt HM & Smith A (1973) 4-Hydroxyisoleucine from seed of Trigonella foenum graecum. Phytochemistry 12: 17071711.
  • Hall TR, Wallin R, Reinhart GD & Hutson SM (1993) Branched chain aminotransferase isoenzymes. J Biol Chem 268: 30923098.
  • Horswill AR & Escalante-Semerena JC (1999) Salmonella typhimurium LT2 catabolizes propionate via the 2-methylcitric acid cycle1. J Bacteriol 181: 56155623.
  • Izard T & Blackwell NC (2000) Crystal structures of the metal-dependent 2-dehydro-3-deoxy-galactarate aldolase suggest a novel reaction mechanism. EMBO Journal 19: 38493856.
  • Jackson J & Bessler R (1981) Clinical pharmacology of sulfonylurea hypoglycemic agents. Drugs 22: 211245.
  • Jennings A, Wilson R & Ward R (1989) Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. Diabetes Care 12: 203208.
  • Liu WT, Marsh TL, Cheng H & Forney LJ (1997) Characterization of microbial diversity by determining terminal restriction fragment length polymorphisms of genes encoding 16S rRNA. Appl Environ Microbiol 63: 45164522.
  • Mamer OA & Reimer MLJ (1992) On the mechanisms of the formation of L-alloisoleucine and the 2-hydroxy-3-methylvaleric acid stereoisomers from L-isoleucine in maple syrup urine disease patients and in normal humans. J Biol Chem 267: 2214122147.
  • Mushkambarov NN (1996) Analytical Biochemistry, Vol. 3. Forwarder, Moscow.
  • Rolland-Fulcrand V, Rolland M, Roumestant M-L & Martinez J (2004) Chemoenzymatic synthesis of enantiomerically pure (2S,3R,4S)-4-hydroxyisoleucine, an insulinotropic amino acid isolated from fenugreek seeds. Eur J Org Chem 2004: 873877.
  • Romine MF, Stillwell LC, Wong K-K, Thurston SJ, Sisk EC, Sensen C, Gaasterland T, Fredrickson JK & Saffer JD (1999) Complete sequence of a 184-kilobase catabolic plasmid from Sphingomonas aromaticivorans F199. J Bacteriol 181: 15851602.
  • Sauvaire Y, Petit P, Broca C et al. (1998) 4-Hydroxyisoleucine: a novel amino acid potentiator of insulin secretion. Diabetes 47: 206210.
  • Takahashi Y, Kato K, Hayashizaki Y, Wakabayashi T, Ohtsuka E, Matsuki S, Ikehara M & Matsubara K (1985) Molecular cloning of the human cholecystokinin gene by use of a synthetic probe containing deoxyinosine. Proc Natl Acad Sci USA 82: 19311935.
  • Wang Q, Ouazzani J, Sasaki NA & Potier P (2002) A practical synthesis of (2S,3R,4S)-4-hydroxyisoleucine, a potent insulinotropic a-amino acid from fenugreek. Eur J Org Chem 834839.
  • Wright A, Blewett A, Fulop V, Cooper R, Burrows S, Jones C & Roper D (2002) Expression, purification, crystallization and preliminary characterization of an HHED aldolase homologue from Escherichia coli K12. Acta Crystallogr D Biol Crystallogr 58: 21912193.